Methods of treating degenerative diseases/injuries
OwnerConnie L. Erickson-Miller, Julian Jenkinsinventors
Life of this patent
Estimating the term…
Abstract
Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
Claims6
An in vitro or ex vivo method of enhancing the differentation of blood components in human fetal cord blood into functional cells which method comprises the addition of an effective amount of a non-peptide TPO receptor agonist selected from:
- 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
- or a pharmaceutically acceptable salt thereof, and
- 3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
- or a pharmaceutically acceptable salt thereof;
- to a culture medium containing human fetal cord blood;
- followed by optional isolation of the functional cells.
A method of transfusing human fetal cord blood which method comprises the addition of an effective amount of a non-peptide TPO receptor agonist selected from:
- 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
- or a pharmaceutically acceptable salt thereof, and
- 3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
- or a pharmaceutically acceptable salt thereof:
- to a patient receiving human fetal cord blood.
An in vitro or ex vivo method of enhancing the differentation of embryonic stem cells into functional cells which method comprises the addition of an effective amount of a non-peptide TPO receptor agonist selected from:
- 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
- or a pharmaceutically acceptable salt thereof, and
- 3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
- or a pharmaceutically acceptable salt thereof;
- to a culture medium containing embryonic stem cells;
- followed by isolation of the functional cells.
Dependencies are inferred from the claim text.